A 40% premium! GlaxoSmithKline plc Sponsored ADR (GSK.US) plans to acquire Nuvalent (NUVL.US) for $10.6 billion, stepping up its presence in the cancer drug sector.

GlaxoSmithKline plc Sponsored ADR (GSK.US) has agreed to acquire the oncology drug company Nuvalent (NUVL.US) for $10.6 billion. GlaxoSmithKline plc Sponsored ADR announced on Tuesday that it will acquire Nuvalent for $124 per share in cash, a 40% premium over the company's closing price on Monday. The acquisition marks a significant expansion of GlaxoSmithKline plc Sponsored ADR's cancer business. Since the British pharmaceutical company re-entered the oncology field in 2019, its cancer product portfolio has been steadily growing. This deal is also the first major acquisition since CEO Luke Miles took office. Since taking over earlier this year, Miles has been focused on revitalizing GlaxoSmithKline plc Sponsored ADR. The company has long lacked a sense of adventure and has struggled to alleviate investors' concerns about its pipeline of drugs. Nuvalent focuses on developing small molecule precision targeted therapies for various tumors, including lung cancer. The company's stock price has already dropped 12% this year, with a market value close to $7 billion. Through the acquisition, GlaxoSmithKline plc Sponsored ADR will gain access to two drugs that are in late-stage clinical trials and are expected to be approved for market by the US Food and Drug Administration later this year. If approved, both drugs could be major breakthroughs, according to GlaxoSmithKline plc Sponsored ADR. The acquisition of Nuvalent is expected to have no impact on GlaxoSmithKline plc Sponsored ADR's performance guidance for this year and is expected to drive revenue growth starting in 2027. Nuvalent's two main drugs are targeted towards non-small cell lung cancer patients with specific genetic mutations. These genetic mutations typically affect non-smokers. In January, GlaxoSmithKline plc Sponsored ADR agreed to acquire the US biotech company Rapt Therapeutics for $2.2 billion, which focuses on developing drugs for inflammation and immune diseases. Additionally, GlaxoSmithKline plc Sponsored ADR has also acquired a drug for treating pulmonary arterial hypertension through another deal. GlaxoSmithKline plc Sponsored ADR stated that the acquisition of Nuvalent is expected to be completed in the third quarter after regulatory approval. The transaction will be mainly financed through new and existing debt as well as cash, and will not impact GlaxoSmithKline plc Sponsored ADR's credit rating.